on SENSORION (EPA:ALSEN)
Sensorion Completes Enrollment for Audiogene Phase 1/2 Trial
On December 27, 2024, Sensorion announced the successful completion of patient enrollment in the first cohort of its Audiogene Phase 1/2 clinical trial. This trial involves SENS-501, a gene therapy aimed at treating hearing loss due to otoferlin gene mutations. The trial targets infants and toddlers aged 6 to 31 months.
The first cohort has three patients, with the last patient receiving the SENS-501 injection in December 2024. The surgical administration was tolerated without serious adverse events. The trial's goal is to measure SENS-501's capacity to restore hearing and facilitate normal speech development in these young patients.
Sensorion's CEO, Nawal Ouzren, emphasized the trial's progress as a major achievement and anticipates the 2025 KOL event where additional data will be presented and analyzed.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all SENSORION news